To report 2 cases of nonoperable intracranial bleeding associated with apixaban managed by 3-factor prothrombin complex concentrate (PCC3).
Case Summaries:
Case 1 presented with a 1.3-cm left parieto-occipital hemorrhage and a thin subdural hematoma (SDH) on the left tentorium of the brain about 6 hours after his last dose of apixaban. Case 2 presented with a 4-mm left parafalcine SDH with time of most recent apixaban dose unknown. The patients received 24.9 to 25.5 U/kg of PCC3 with none to 1 U fresh frozen plasma (FFP) and demonstrated minimal or no progression in lesions measured by repeat computed tomography (CT) after treatment. One patient was discharged to a skilled nursing facility after 8 days; the other patient was discharged to home after 18 days.
Discussion:
Apixaban has no specific antidote. Current bleeding management strategies are based on expert opinion. The risks and benefits for differing strategies are unclear, and little clinical experience for managing apixaban-associated intracranial bleeding has been reported to date. These cases describe the clinical use of PCC3 to manage parieto-occipital and subdural hemorrhage associated with apixaban in events not requiring surgical intervention.
Conclusion:
In these 2 cases, 25 U/kg PCC3, with none to one unit FFP, ceased apixaban-associated intracranial bleeding without apparent thrombogenic complications.
BarnesGDAgenoWAnsellJ. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH: comment. J Thromb Haemost. 2015;13(11):2130–2132. doi:10.1111/jth.13124.
Savaysa® [package insert]. Tokyo, Japan: Daiichi Sankyo Co., LTD; 2015.
6.
GrangerCBAlexanderJHMcMurrayJJV. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa1107039.
7.
AgnelliGBullerHRCohenA; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa1302507.
ConnollySJMillingTJEikelboomJW; ANNEXA-4 Investigators. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–1141. doi:10.1056/NEJMoa1607887.
10.
EscolarGFernandez-GallegoVArellano-RodrigoE. Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood. PLoS One. 2013;8(11):1–7. doi:10.1371/journal.pone.0078696.
11.
SiegalDM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis. 2015;39(3):395–402. doi:10.1007/s11239-015-1167-9.
ChapmanSAIrwinEDAbou-KaramNM. Comparison of 3-factor prothrombin complex concentrate and low-dose recombinant factor viia for warfarin reversal. World J Emerg Surg. 2014;9(1):27. doi:10.1186/1749-7922-9-27.
14.
GonsalvesWIGuptaVPatnaikMM. Management of bleeding complications in patients on new oral anticoagulants. 2014;2:1–6.
15.
EnriquezALipGYHBaranchukA. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace. 2016;18(7):955–964. doi:10.1093/europace/euv030.
16.
RinehartDRLockhartNRHamiltonLA. Management of apixaban-associated subdural hematoma: a case report on the use of factor eight inhibitor bypassing activity. Crit Care Med. 2015;43(6): e203–e207. doi:10.1097/CCM.0000000000000909.
17.
FronteraJALewinJJRabinsteinAA. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care. 2016;24(1):6–46. doi:10.1007/s12028-015-0222-x.
18.
LiottaEMLevasseur-FranklinKENaidechAM. Reversal of the novel oral anticoagulants dabigatran, rivoraxaban, and apixaban. Curr Opin Crit Care. 2015;21(2):127–133. doi:10.1097/MCC.0000000000000181.
19.
SteinerTBöhmMDichgansM. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102(6):399–412. doi:10.1007/s00392-013-0560-7.
20.
HollandLWarkentinTERefaaiM. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion. 2009;49(6):1171–1177. doi:10.1111/j.1537-2995.2008.02080.x.
21.
MartinACLe BonniecBFischerAM. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168(4):4228–4233. doi:10.1016/j.ijcard.2013.07.152.
22.
WójcikCSchymikMLCureEG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. Int J Emerg Med. 2009;2(4):217–225. doi:10.1007/s12245-009-0125-8.
23.
LeviMLevyJHAndersenHF. Safety of recombinant activated factor VII in randomized clinical trials. N Engl J Med. 2010;363(19):1791–1800. doi:10.1056/NEJMoa1006221.
24.
MajeedAEeldeAÅgrenA. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res. 2012;129(2):146–151. doi:10.1016/j.thromres.2011.07.024.
25.
CabralKPFraserGLDupreyJ. Prothrombin complex concentrates to reverse warfarin-induced coagulopathy in patients with intracranial bleeding. Clin Neurol Neurosurg. 2013;115(6):770–774. doi:10.1016/j.clineuro.2012.07.006.
26.
DentaliFMarchesiCPierfranceschiMG. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. Thromb Haemost. 2011;106(3):429–438. doi:10.1160/TH11-01-0052.
27.
MeschiaJFBushnellCBoden-AlbalaB. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754–3832. doi:10.1161/STR.0000000000000046.
28.
GonsalvesWIPruthiRKPatnaikMM. The new oral anticoagulants in clinical practice. Mayo Clin Proc. 2013;88(5):495–511. doi:10.1016/j.mayocp.2013.03.006.
29.
KaatzSKouidesPAGarciaDA. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol. 2012;87(S1):S141–S145. doi:10.1002/ajh.23202.
NutescuEADagerWEKalusJS. Management of bleeding and reversal strategies for oral anticoagulants: clinical practice considerations. Am J Health-Syst Pharm. 2013;70(21):1914–1929.
32.
SiegalDMCurnutteJTConnollySJ. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413–2424. doi:10.1056/NEJMoa1510991.
